BidaskClub upgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) from a hold rating to a buy rating in a research note issued to investors on Wednesday, December 27th.
AIMT has been the subject of a number of other reports. Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the company a buy rating in a report on Saturday, October 21st. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a sell rating to a hold rating in a report on Tuesday, August 29th. Wedbush reiterated an outperform rating and issued a $70.00 target price on shares of Aimmune Therapeutics in a research note on Friday, December 1st. Roth Capital started coverage on shares of Aimmune Therapeutics in a research note on Monday, November 20th. They issued a buy rating and a $60.00 target price for the company. Finally, ValuEngine cut shares of Aimmune Therapeutics from a hold rating to a sell rating in a research note on Friday, December 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Aimmune Therapeutics has an average rating of Hold and a consensus price target of $55.43.
Aimmune Therapeutics (AIMT) opened at $38.65 on Wednesday. Aimmune Therapeutics has a one year low of $15.97 and a one year high of $40.00. The firm has a market cap of $1,970.00 and a price-to-earnings ratio of -16.52.
In other news, insider Susan E. Barrowcliffe sold 75,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $37.14, for a total transaction of $2,785,500.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Stephen George Dilly sold 1,154 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $26.24, for a total transaction of $30,280.96. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 137,946 shares of company stock valued at $4,991,189. Company insiders own 17.59% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asset Management L.P. boosted its position in shares of Aimmune Therapeutics by 10.2% during the third quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock worth $27,222,000 after purchasing an additional 101,855 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Aimmune Therapeutics during the second quarter worth $442,000. Goldman Sachs Group Inc. boosted its position in shares of Aimmune Therapeutics by 139.9% during the second quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock worth $4,675,000 after purchasing an additional 132,603 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Aimmune Therapeutics by 16.9% during the second quarter. Bank of New York Mellon Corp now owns 131,353 shares of the biotechnology company’s stock worth $2,700,000 after purchasing an additional 19,016 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Aimmune Therapeutics during the second quarter worth $360,000. 73.34% of the stock is currently owned by institutional investors.
WARNING: “Aimmune Therapeutics (AIMT) Upgraded at BidaskClub” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://stocknewstimes.com/2018/01/12/aimmune-therapeutics-aimt-upgraded-by-bidaskclub-to-buy.html.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.